Tuberculosis

As an official AI partner of the Central TB Division (CTD), we are developing multiple interventions across the TB care cascade and helping India’s National TB Elimination Programme (NTEP) become AI-ready.

Line Probe Assay

The TB LPA solution active pilot is expected to launch by mid-Oct 2021 with a gradual scale up to full deployment across all 64 CDST Labs.

Deploy to

64 Culture and Drug Sensitivity Test (CDST) Labs by April 2022

Number of patient tests impacted:

~4 Lakhs (estimated 6 lakhs in 2022)

Potential Impact

  • Overall reduction in turnaround time for every patient tested of upto ½ day.
  • Faster treatment initiation, estimated 300,000 patient-days saved annually.
  • Increase in treatment success by averting incorrect diagnosis. An estimated 12,000 patient beneficiaries per year prevented from initiating the wrong regimen.

Loss to Follow Up

57,000

patients targeted by AI model

14,250

fewer LFU patients/year

1,100+

deaths prevented

*Assuming an AI model sensitivity of 57% (at 20% targeting) and pan-India rollout (2,40,000 patients) of the program through CTD (with 25% program efficiency).